Literature DB >> 18468781

Overexpression of ELAV-like protein HuR is associated with increased COX-2 expression in atrophy, high-grade prostatic intraepithelial neoplasia, and incidental prostate cancer in cystoprostatectomies.

Francesca Barbisan1, Roberta Mazzucchelli, Alfredo Santinelli, Antonio Lopez-Beltran, Liang Cheng, Marina Scarpelli, Francesco Montorsi, Rodolfo Montironi.   

Abstract

BACKGROUND: The human ELAV-like protein HuR regulates the stability of several mRNA targets, including that of cyclooygenase-2 (COX-2). Their expression in prostatic carcinogenesis is uncertain.
OBJECTIVE: To analyze HuR and COX-2 expression in cystoprostatectomies (CyPs) with incidental prostate cancer and compare their expression with those in radical prostatectomies (RPs) with clinically detected cancer. DESIGN, SETTING, AND PARTICIPANTS: HuR and COX-2 were immunohistochemically evaluated in normal-looking epithelium (NEp), atrophy, high-grade prostatic intraepithelial neoplasia (HGPIN), and prostate carcinoma (PCa) in 20 CyPs and 20 RPs, both types of specimens with pT2a Gleason score 6 PCa. MEASUREMENTS: At least 1000 cells were counted in contiguous 400X microscopic fields in each case, separately for NEp, atrophy, HGPIN, and PCa. RESULTS AND LIMITATIONS: There was an increase in the percentage of secretory cells with cytoplasmic HuR staining from NEp to atrophy, HGPIN, and PCa. The mean percentages in NEp, atrophy, and HGPIN adjacent to PCa were greater than away from cancer, both in the CyP and RPs. There was a trend towards a reduced nuclear HuR expression in atrophy, HGPIN, and PCa, compared to NEp. COX-2 staining was seen in the cytoplasm of the basal and secretory cells. There was a reduction in the mean proportion of positive basal cells and progressive increase in the percentage of positive secretory cells from atrophy to HGPIN and PCa, compared to NEp. Cytoplasmic HuR overexpression was correlated with COX-2 expression. There was no difference in HuR and COX-2 expression between cancers with tumour volume <0.5 ccm or >0.5 ccm. The limitations of this study were the small number of cases investigated and lack of a control group without cancer.
CONCLUSIONS: The secretory cells showed shift in HuR staining from nuclear in NEp to cytoplasmic in PCa. This is associated with a parallel shift in COX-2 expression from basal to secretory cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18468781     DOI: 10.1016/j.eururo.2008.04.043

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  17 in total

Review 1.  Posttranscriptional regulation of cancer traits by HuR.

Authors:  Kotb Abdelmohsen; Myriam Gorospe
Journal:  Wiley Interdiscip Rev RNA       Date:  2010-05-06       Impact factor: 9.957

2.  The RNA-binding protein HuR opposes the repression of ERBB-2 gene expression by microRNA miR-331-3p in prostate cancer cells.

Authors:  Michael R Epis; Andrew Barker; Keith M Giles; Dianne J Beveridge; Peter J Leedman
Journal:  J Biol Chem       Date:  2011-10-04       Impact factor: 5.157

3.  Identification and validation of novel small molecule disruptors of HuR-mRNA interaction.

Authors:  Xiaoqing Wu; Lan Lan; David Michael Wilson; Rebecca T Marquez; Wei-Chung Tsao; Philip Gao; Anuradha Roy; Benjamin Andrew Turner; Peter McDonald; Jon A Tunge; Steven A Rogers; Dan A Dixon; Jeffrey Aubé; Liang Xu
Journal:  ACS Chem Biol       Date:  2015-03-17       Impact factor: 5.100

Review 4.  Clinical significance of HuR expression in human malignancy.

Authors:  Ioly Kotta-Loizou; Constantinos Giaginis; Stamatios Theocharis
Journal:  Med Oncol       Date:  2014-08-13       Impact factor: 3.064

5.  Cytoplasmic expression of the ELAV-like protein HuR as a potential prognostic marker in esophageal squamous cell carcinoma.

Authors:  Cong Zhang; Guoliang Xue; Jingwang Bi; Ming Geng; Huili Chu; Yaping Guan; Jun Wang; Baocheng Wang
Journal:  Tumour Biol       Date:  2013-07-20

6.  HuR mediated post-transcriptional regulation as a new potential adjuvant therapeutic target in chemotherapy for pancreatic cancer.

Authors:  Aldona Jakstaite; Aurelija Maziukiene; Giedre Silkuniene; Kristina Kmieliute; Antanas Gulbinas; Zilvinas Dambrauskas
Journal:  World J Gastroenterol       Date:  2015-12-14       Impact factor: 5.742

Review 7.  Multiple functions of HuR in urinary tumors.

Authors:  Fa Zhang; Zhonglin Cai; Haidi Lv; Wenjuan Li; Mengtian Liang; Xupan Wei; Fenghai Zhou
Journal:  J Cancer Res Clin Oncol       Date:  2018-10-28       Impact factor: 4.553

Review 8.  HuR function in disease.

Authors:  Subramanya Srikantan; Myriam Gorospe
Journal:  Front Biosci (Landmark Ed)       Date:  2012-01-01

Review 9.  Multiple functions of the RNA-binding protein HuR in cancer progression, treatment responses and prognosis.

Authors:  Jun Wang; Yan Guo; Huili Chu; Yaping Guan; Jingwang Bi; Baocheng Wang
Journal:  Int J Mol Sci       Date:  2013-05-10       Impact factor: 5.923

10.  Prostate chronic inflammation type IV and prostate cancer risk in patients undergoing first biopsy set: Results of a large cohort study.

Authors:  Antonio Benito Porcaro; Giovanni Novella; Matteo Balzarro; Guido Martignoni; Matteo Brunelli; Giovanni Cacciamani; Maria A Cerruto; Walter Artibani
Journal:  Asian J Urol       Date:  2015-09-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.